• Mashup Score: 2
    BiTEs for the treatment of multiple myeloma - 3 year(s) ago

    Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, gives an overview of his presentation at EMN 2021 on the…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      An insightful review of the latest biological and clinical data using BiTEs for the treatment of #MultipleMyeloma, w/ Hermann Einsele (@Uni_WUE): https://t.co/4M1EMQZAt9 #EMN #EMN21 #HemOnc #ImmunoOnc #Myeloma #MMSM #MyelomaACTIONmonth #IAMRESILIENT2021 #CTSM #TrialUpdate

  • Mashup Score: 0
    POLLUX & CASTOR analysis: MRD- with dara-combination regimens - 3 year(s) ago

    Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the results of an analysis of measurable residual…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #POLLUX & #CASTOR analysis: MRD-negativity with dara-combination regimens, w/ @SagarLonialMD of @WinshipAtEmory: https://t.co/gu1VBM7qiJ @EmoryMedicine #EMN #EMN21 #HemOnc #ImmunoOnc #MultipleMyeloma #Myeloma #MMSM #MyelomaACTIONmonth #IAMRESILIENT2021 #mmMRD #CTSM #trialupdate

  • Mashup Score: 0
    Multiple Myeloma - VJHemOnc - 3 year(s) ago

    Multiple Myeloma (MM) is a neoplasm of plasma cells and is the second most common hematological malignancy, accounting for 1% of all malignancies.

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      It the final day of #EMN21! Catch all the updates: 👉https://t.co/FcghXrybpe👈 #MMsm #MultipleMyeloma #BMTsm #mmMRD #CTsm #TrialUpdate #ImmunoOnc #CART #Tcellrx #Oncology #EMN2021 #EMN https://t.co/zyxrQ0Mn38

  • Mashup Score: 0
    Real-world data: KRd in R/R multiple myeloma - 3 year(s) ago

    Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, summarises the key findings from a real-world analysis of carfilzomib plus…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Real-world data: KRd in R/R #MultipleMyeloma w/ Elena Zamagni: Watch: 👉https://t.co/vsXTDgsIzD👈 #EMN21 #EMN #MMsm #BMTsm #mmMRD #EMN2021 #CTsm #TrialUpdate #ImmunoOnc #Oncology @UniboMagazine

  • Mashup Score: 7
    FORTE: impact of gain and amplification of 1q in myeloma - 3 year(s) ago

    Mattia D’Agostino, MD, University of Torino, Turin, Italy, gives an overview of his talk at EMN 2021 on the prognostic…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Mattia D’Agostino of @unito joined us for a discussion on FORTE, focusing on the impact of gain and amplification of 1q in #Myeloma Watch: 👉https://t.co/Z1RS85frIc👈 #EMN21 #EMN #MMsm #MultipleMyeloma #EMN2021 #BMTsm #mmMRD #CTsm #TrialUpdate #ImmunoOnc #Tcellrx #Oncology

  • Mashup Score: 0
    Targeting CXCR4 in Waldenström’s macroglobulinemia - 3 year(s) ago

    Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the significance of CXCR4 in Waldenström’s macroglobulinemia. Mutations in CXCR4…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Targeting CXCR4 in Waldenström's macroglobulinemia w/ Steve Treon of @DanaFarber: Watch: 👉https://t.co/asgcX9vsSQ👈 #EMN21 #EMN #MultipleMyeloma #EMN2021 #MMsm #BMTsm #mmMRD #CTsm #TrialUpdate #ImmunoOnc #Oncology https://t.co/TNk3M4cTVx

  • Mashup Score: 1
    Frailty subgroup analysis of the MAIA trial - 3 year(s) ago

    Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses results from a frailty subgroup…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Frailty subgroup analysis of the MAIA trial w/ @profBigG: Watch: 👉https://t.co/NGucgbXAti👈 #EMN21 #EMN #MultipleMyeloma #EMN2021 #MMsm #BMTsm #mmMRD #CTsm #TrialUpdate #ImmunoOnc #Oncology @LeedsHospitals

  • Mashup Score: 0
    Multiple Myeloma - VJHemOnc - 3 year(s) ago

    Multiple Myeloma (MM) is a neoplasm of plasma cells and is the second most common hematological malignancy, accounting for 1% of all malignancies.

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Get all the #EMN21 updates! 👉https://t.co/FcghXrybpe👈 #MMsm #MultipleMyeloma #BMTsm #mmMRD #CTsm #TrialUpdate #ImmunoOnc #CART #Tcellrx #Oncology #EMN2021 #EMN https://t.co/SKSQEgFWVK

Load More